As of close of business last night, Kazia Therapeutics Limited ADR’s stock clocked out at $0.46, up 13.33% from its previous closing price of $0.41. In other words, the price has increased by $+0.0540 from its previous closing price. On the day, 1097791 shares were traded.
Ratios:
To gain a deeper understanding of KZIA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.71 and its Current Ratio is at 0.71. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on October 14, 2021, initiated with a Buy rating and assigned the stock a target price of $18.
On January 05, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $17.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KZIA now has a Market Capitalization of 12.10M and an Enterprise Value of 9.84M. Its current Enterprise Value per Revenue stands at -1.34k whereas that against EBITDA is -0.44.
Stock Price History:
Over the past 52 weeks, KZIA has reached a high of $1.68, while it has fallen to a 52-week low of $0.19. The 50-Day Moving Average of the stock is 0.2856, while the 200-Day Moving Average is calculated to be 0.6378.
Shares Statistics:
It appears that KZIA traded 849.76K shares on average per day over the past three months and 500.48k shares per day over the past ten days. A total of 23.63M shares are outstanding, with a floating share count of 23.62M. Shares short for KZIA as of Feb 29, 2024 were 45.93k with a Short Ratio of 0.29, compared to 181.72k on Jan 31, 2024.
Earnings Estimates
As of right now, 0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
Based on 1 analysts’ estimates, the company’s revenue will be $510k in the next fiscal year. The high estimate is $510k and the low estimate is $510k. The average revenue growth estimate for next year is up 750.00% from the average revenue estimate for this year.
